The federal government has called for increased African-led research, stronger partnerships and sustainable financing to improve the prevention, diagnosis and treatment of hepatobiliary cancers.

The Minister of State for Health and Social Welfare, Iziaq Salako, made the call at the fifth Africa Hepato-Pancreato-Biliary Cancer Consortium (AHPBCC) Conference on Thursday in Abuja.

Mr Salako, who was represented by Ali Gombe, director of clinical services, National Institute for Cancer Research and Treatment (NICRAT), said African countries needed evidence that reflected their populations, disease patterns and health system realities to guide effective cancer interventions.

He called for greater investment in research covering epidemiology, risk factors, genetics, prevention, diagnosis and treatment, supported by cancer registries, clinical trials and collaborative research networks.

He also advocated the use of digital health, genomics, and artificial intelligence to strengthen cancer prevention, diagnosis, treatment, and surveillance.

“Research should translate into affordable, accessible, sustainable interventions for African populations,” Mr Salako said, describing AHPBCC as a valuable platform for multidisciplinary collaboration.

He said Nigeria was strengthening cancer prevention and early detection while expanding diagnostic and treatment capacity under the National Strategic Cancer Control Plan.

According to him, cancer control required an integrated continuum covering risk reduction, health education, early diagnosis, referral, surgery, systemic therapy, radiotherapy, palliative care and survivorship.

Mr Salako said the government was strengthening financial protection through the National Cancer Health Fund, although hepatobiliary cancers were currently excluded, with plans to expand its coverage.

He also cited the Nigerian Cancer Access Partnership, which provides 50 to 60 per cent discounts on anti-cancer medicines, as well as plans for a catastrophic health fund.

He said prevention remained central, particularly through tobacco control, healthier lifestyles and control of viral infections associated with cancer.

“For liver cancer, particularly hepatitis, emphasis is placed on prevention and control of hepatitis B and C through vaccination, screening, diagnosis and treatment,” he said.

Mr Salako said Nigeria was also investing in specialists, laboratories, cancer treatment centres and research infrastructure, alongside mentorship, fellowships, specialised training and knowledge exchange.

He stressed that no country or institution could address the cancer burden alone, urging governments, researchers, academia, civil society, development partners and the private sector to work together.

Abdulfatai Olokoba, president, Society of Gastroenterology and Hepatology in Nigeria (SOGHIN), said the conference exemplified such partnerships among organisations working across the cancer and digestive disease fields.

Mr Olokoba said the collaboration brought together oncologists, surgeons, pathologists, radiologists, scientists, nurses and other specialists to improve knowledge and skills.

He said hepatobiliary cancers remained particularly challenging in Africa because of late presentation, limited resources and capacity gaps, as well as inadequate awareness.

According to him, the three-day meeting would examine prevention, treatment, research, survivorship, public health education, vaccination, surgical innovations and approaches tailored to African realities.

Lewis Roberts, president, African Institute for Liver and Digestive Diseases (AILDD), said hepatobiliary cancers often occurred at younger ages in Africa, resulting in substantial years of life lost.

Mr Roberts said prevention and early detection should remain priorities, noting that cancers diagnosed early were generally more treatable and less costly to manage.

He said conference workshops were examining earlier detection of bile duct, pancreatic and liver cancers using advanced endoscopic procedures, endoscopic ultrasound, ultrasound and FibroScan.

He said research should also explore blood-based methods that could detect cancers earlier without requiring patients to undergo more demanding procedures.

For patients diagnosed at advanced stages, Mr Roberts said research into tumour biology could enable targeted chemical and immune-based treatments tailored to individual cancers.

ALSO READ: Four in 10 cancers worldwide could be prevented, WHO warns

He, however, noted that the cost of some advanced treatments, including monoclonal antibodies, remained beyond the reach of many African health systems.

“We have to start now, and we have to start here,” he said, urging African scientists to develop solutions suited to the continent’s realities.

The News Agency of Nigeria (NAN) reports that the conference, attended by more than 300 delegates from over 30 countries, focuses on prevention, treatment, research and survivorship for cancers affecting the liver, pancreas and biliary tract.

The conference, which began on Wednesday and ends on Saturday, brought together experts from Africa, the United States, Europe, Asia and other regions. (NAN)

The World Health Organisation (WHO) has recommended a Phase III trial of an Ebola vaccine to test whether it can protect against Bundibugyo virus disease.

WHO Director-General, Tedros Ghebreyesus, disclosed this in a video posted on his official X account on Thursday.

Ghebreyesus said two vaccines specifically developed against the Bundibugyo virus had entered Phase I safety trials in humans. At the same time, new animal studies had shown promising evidence that Ervebo, an Ebola vaccine, could also provide cross-protection against the virus.

He said the findings prompted WHO to recommend Ervebo for inclusion in a Phase III trial, which the organisation hopes to begin as soon as possible.

However, it is not yet known whether Ervebo can protect humans against Bundibugyo virus disease.

Mr Ghebreyesus said the Phase III trial would help establish whether the vaccine is safe and effective and could provide evidence needed to make it available for the current outbreak and future outbreaks.

No licensed vaccines

The development comes as the Bundibugyo virus outbreak in the DRC has become the second-largest Ebola outbreak on record.

As of Thursday, the country had recorded 4,449 confirmed cases and 2,061 deaths across five provinces and 53 health zones, according to the WHO.

The health agency said the outbreak was spreading faster than any previous Ebola outbreak at the same stage and could surpass the 2014–2016 West African outbreak, which remains the largest on record, with more than 28,000 cases and 11,000 deaths reported in Guinea, Liberia and Sierra Leone.

Bundibugyo virus is one of the viruses in the Ebola family that can cause severe and often fatal disease in humans.

Unlike Ebola virus disease caused by the Ebola virus, there is currently no licensed vaccine specifically approved for the prevention of Bundibugyo virus disease.

WHO said in June that Ervebo, the only licensed and WHO-prequalified Ebola vaccine, is approved for Ebola virus disease but not for Bundibugyo virus disease.

The current outbreak was first detected in the DRC in May, following an unexplained cluster of deaths in Ituri Province that was investigated. Laboratory testing confirmed Bundibugyo virus disease, prompting the DRC government to declare its 17th Ebola outbreak.

Uganda also confirmed imported cases linked to the outbreak in the DRC. WHO subsequently determined that the outbreak in the two countries constituted a Public Health Emergency of International Concern.

Previous Bundibugyo virus outbreaks have had case fatality rates between 30 and 50 per cent, according to the WHO.

PREMIUM TIMES reported on 9 August that WHO had already recommended Ervebo for evaluation in a randomised clinical trial after reviewing evidence suggesting that it could provide some protection against Bundibugyo virus.

Treatment advancement

Mr Ghebreyesus also disclosed progress in research into treatments for Bundibugyo virus disease.

He said a WHO-sponsored partners trial had reached 100 patients.

The trial is assessing potential treatments for the disease and is intended to generate evidence on which therapies can improve outcomes for infected patients.

READ ALSO: DRC Ebola outbreak becomes second-largest on record WHO

Mr Ghebreyesus said the milestone showed that research could be mobilised rapidly and responsibly even during a difficult outbreak.

He called on partners to support and accelerate the vaccine trial, while emphasising that the response requires collaboration among the DRC government, WHO, Africa Centres for Disease Control and Prevention (CDC) and other partners.